Ole Andreas Halvorsen is 10% Owner at Urovant Sciences Ltd. (UROV). They have made 12 open-market trades across 7 companies since 2014, most recently 2025-06-27.
CIK 0001133006
9 open-market purchases totalling $67.3M since 2014, against 3 sales. Across 9 scored buys the stock is down 7.9% at ninety days, and 9.5 points behind the S&P over the same stretch.
9 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 33% | 44% | 33% |
| Avg Move | -2.3% | -0.2% | -7.9% |
| Alpha | -0.1% | -1.6% | -9.5% |
| Scored | 9 | 9 | 9 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BBIO | SELL | 2025-06-27 | 2025-07-01 | $44.00 | $154.0M | +12.4% | +11.4% | +22.5% |
| PRCT | BUY | 2021-09-17 | 2021-09-21 | $35.00 | $14.0M | -0.1% | +10.3% | -35.2% |
| ZNTL | SELL | 2020-12-01 | 2020-12-03 | $50.50 | $25.3M | +2.3% | +1.8% | -15.8% |
| ADPT | SELL | 2020-01-28 | 2020-01-30 | $24.98 | $245.4M | +3.6% | -11.7% | +7.1% |
| ADPT | BUY | 2019-07-01 | 2019-07-02 | $20.00 | $5.0M | -3.6% | -2.3% | -21.9% |
| UROV | BUY | 2019-06-17 | 2019-06-19 | $8.34 | $262K | -5.1% | +3.9% | +15.5% |
| UROV | BUY | 2019-05-21 | 2019-05-23 | $8.52 | $85K | +3.6% | +4.3% | +1.6% |
| UROV | BUY | 2019-05-21 | 2019-05-23 | $8.22 | $163K | +3.6% | +4.3% | +1.6% |
| UROV | BUY | 2019-05-20 | 2019-05-20 | $7.98 | $66K | -6.8% | -0.8% | -4.4% |
| UROV | BUY | 2019-05-16 | 2019-05-20 | $7.54 | $163K | -6.8% | -0.8% | -4.4% |
| AXON | BUY | 2018-12-18 | 2018-12-20 | $1.00 | $10.0M | +4.3% | +17.3% | +26.9% |
| UROV | BUY | 2018-10-01 | 2018-10-03 | $14.00 | $37.5M | +2.7% | -30.9% | -47.3% |
| W | BUY | 2014-11-03 | 2014-11-05 | $25.17 | $30K | -9.0% | -2.4% | -2.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| ZNTL | 3,943,284 | $8.5M |
| EDIT | 1,709,401 | $4.0M |
| API | 196,000 | $851K |
| Total | $42.0B |
Shares reported on the most recent Form 4, priced at the 2025-07-01 close.